The Food and Drug Administration (FDA) has recently approved an innovative obesity medication from Eli Lilly that hold ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

In a report released on December 6, Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), ...

Eli Lilly and Company announced earlier this week ... Lilly markets tirzepatide as Zepbound for obesity and as Mounjaro for type II diabetes. Though demand for the two drugs remains massive ...

Here's how the maker of Mounjaro and Zepbound is looking at southeast Wisconsin and the rest of the state as it continues to grow. Fast-growing drugmaker Eli Lilly and Co. would consider Wisconsin ...

Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has determined that Eli Lilly's (NYSE:LLY) weight-loss drug Mounjaro (tirzepatide) does not need a separate ...

Souring demand for Zepbound, Mounjaro has Eli Lilly planning a $3B expansion that will bring hundreds of jobs to Pleasant Prairie, which the company says is part of its 'critical geography.' ...

Eli Lilly and Novo Nordisk dominate the market ... Lilly makes tirzepatide, which is approved for type 2 diabetes under the name Mounjaro and for weight control under the name Zepbound (though ...

ðÿ €üí—Õ×ï+{v7© ( dÓs]}Ý?)TLè¨0B ÓVþo­2îmŒÈ‹± úœÈûPõR==³p8{» HUõ«g{fú ñùÈ OàÈù vq 26.^f ª6[úÞfž B ÛM}ÿ!¤1‹ Ù ôêP>PuÁé)â&ø¿ÑÝ ¦[n ü¸Ø ...

Eli Lilly is spending another $3 billion to bulk ... demand for injectable products like its diabetes and obesity drugs, Mounjaro and Zepbound. Those drugs brought in a combined $4.4 billion ...